Vepdegestrant

N/A

Report date: 2026/05/14 20:00:28
NMEFirst In Class

Base Information

Drug NameVepdegestrant
Drug Alias NameVEPPANUARV-471PF-07850327
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEstrogen receptors degraders
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[4] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/05/01
Country/TerritoryCzechiaBelgiumBulgaria +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesArvinas IncPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesArvinas Estrogen Receptor IncArvinas Operations IncArvinas Inc +[6] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A